Teriflunomide for treating relapsing–remitting multiple sclerosis

NICE technology appraisals [TA303] Published date:

Teriflunomide is recommended as a possible treatment for adults with active relapsing-remitting multiple sclerosis that isn’t highly active or rapidly evolving severe relapsing-remitting multiple sclerosis.

What does this mean for me?

If you have active relapsing-remitting multiple sclerosis, and your doctor thinks that teriflunomide is the right treatment, you should be able to have the treatment on the NHS.

Teriflunomide should be available on the NHS within 3 months of the guidance being issued.

If you are not eligible for treatment as described above, you should be able to continue taking teriflunomide until you and your doctor decide it is the right time to stop.

Get involved